Video Lectures
State-of-the-industry video lectures by leading urology experts
Latest Videos

TAIPEI, TAIWAN ( - Introduction and Objectives: Interestingly, robot assisted radical prostatectomy (RARP) in the treatment of high-risk prostate cancer has not been well studied to date. We sought to evaluate all patients with high-risk prostate cancer undergoing RARP at our institution.

wceMethods: We performed a single-institution, single-surgeon review of 3,120 patients who underwent RARP from 2005 to 2012. Patients were identified who underwent RARP for high-risk disease as determined by D’Amico classification (Gleason 8–10, stage ≥T2c, and or PSA ≥20). Perioperative data was evaluated from a prospectively maintained RARP database. Treatment was considered a failure with PSA levels ≥0.2.

Results: In total, 319 patients were identified that met high-risk classification. The median age was 61. The median BMI was 28.29. Follow-up ranged from 11 to 98 months. 1-year biochemical recurrence free survival (1-RFS) was 81.8%. 2-year biochemical recurrence free survival (2-RFS) was 63.3%. Gleason score of 8–10 was the most common pre-operative high-risk identifier (64%). Positive surgical margins occurred in 29.8% of patients. Lymph node dissection was performed on 307 patients (96%). The 12 patients that did not receive a lymph node dissection had surgery prior to 2009. In total, 12 patients (3.9%) were found to have positive lymph node involvement.

Conclusions: We present our data for the treatment of high-risk prostate cancer with RARP. Consistent with recent, but limited data, RARP appears to be an effective initial treatment for high-risk prostate cancer. Further follow-up for these patients remains necessary to help better understand long-term outcomes following RARP for high-risk prostate cancer.

Source of Funding: None

Listen to an interview with Benjamin Katz, one of the authors of this study.

Presented by Andrew J. Lightfoot, Giovanni Greaves, Sue-Jean Yu, Elton Llukani, Benjamin F. Katz, Alice McGill, Kelly Monohan, Phillip Mucksavage, and David I. Lee at the 32nd World Congress of Endourology & SWL - September 3 - 7, 2014 - Taipei, Taiwan

University of Pennsylvania, Philadelphia, PA USA 


Upcoming urology industry events
August 1-5, 2018 / Sheraton Philadelphia Society Hill Hotel
SUFU Research Foundation Resident Preceptorship 2018
August 3-4, 2018 / Hyatt Regency Washington on Capitol Hill
Best of ASCO 2018 - Washington, DC
August 10-11, 2018 / The Palmer House Hilton, Chicago, IL
Best of ASCO 2018 - Chicago, IL
August 28-31, 2018 / ICS 2018
International Continence Society 2018
Print publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 2 Issue 4

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor